Vantage logo

The problem with Her2-low testing

Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.